Clinical Studies

The primary focus of EuroVacc’s clinical program is on the development of its leading candidates DNA-C+NYVAC-C. Currently, in collaboration with Agence nationale de recherches sur le sida et les hépatites virales (ANRS), a phase II trial with these vaccine candidates is ongoing in Europe. EuroVacc is also developing collaborations with clinical trial sites in Sub-Saharan Africa to evaluate the DNA-C +NYVAC-C candidate vaccines in the African population who has been hit the hardest by the AIDS epidemic and to prepare for future efficacy trial.
In addition, through the collaboration with EC funded consortium “Evaluation of a New Therapeutic Vaccination Strategy for HIV infection (TheraVac)”, EuroVacc has also sponsored two therapeutic trials of NYVAC-B and MVA-B.
 

Preventative Trials

Protocol Nr.	Description	Sponsors	Trials sites	Status	Publication
EV01	Phase I Safety and Immunogenicity Study of NYVAC-C alone	Imperial College London	Switzerland & UK	Completed	Click here
EV02	Phase I Safety and Immunogenicity comparing DNA-C prime and NYVAC-C boost versus NYVAC-C alone	Eurovacc	Switzerland & UK	Completed	Click here
EV03/ ANRSVAC20	Phase II Immunogenicity and safety of 3 DNA-C prime followed by 1 NYVAC-C boost versus 2 DNA-C prime followed by 2 NYVAC-C boost	EuroVacc & ANRS	Switzerland, UK, Germany, France	Ongoing	Click here

Therapeutic Trials

Protocol Nr.	Description	Sponsors	Trials sites	Status	Publication
Theravac01	Phase I safety of NYVAC-B in chronic HIV-1 infected patients successfully treated with HAART	Eurovacc	Switzerland	Completed	Click here
TheraVac02	Phase I safety of MVA-B in chronic HIV-1 infected patients successfully treated with HAART	Eurovacc	The Netherlands	Completed	Click here